Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical SHR-A2102 ADC for high-risk non-muscle-invasive bladder cancer
ChiCTR2500106965Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-A2102 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Shanghai General Hospital. Primary endpoints: Dose-limiting toxicity (DLT), Maximum tolerated dose (MTD) and 2 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
SHR-A2102
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2500106965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106965.